Please assess the completion status of the following clinical trial:

Trial Title: Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ages 6 to 12.~2. ADHD diagnosis with ADHD Rating Scale - 4th Edition scores ≥ 90th percentile.~3. In need of treatment for ADHD and able to have 2-day washout from previous medication.~4. Females of child-bearing potential not pregnant and practice birth control.~5. Subject and parent/guardian willing to comply with protocol.~6. Signed consent and assent.~Exclusion Criteria:~1. Estimated Full Scale intellectual level below 80 using Wechsler Abbreviated Scale of Intelligence.~2. Current primary psychiatric diagnosis of: severe anxiety disorder, conduct disorder, psychotic disorders, pervasive developmental disorder, eating disorder, obsessive-compulsive disorder, major depressive disorder, bipolar disorder, substance use disorder, chronic tic disorder, personal or family history of Tourette's Syndrome.~3. Chronic medical illnesses: seizure, hypertension, thyroid disease, cardiac, family history of sudden death, glaucoma.~4. Use of psychotropic CNS meds having effect exceeding 14 days from screening.~5. Planned use of prohibited drugs.~6. Is pregnant or breast-feeding.~7. Significant ECG or laboratory abnormalities.~8. Experimental drug or medical device within 30 days prior to screening.~9. Hypersensitivity to methylphenidate.~10. Inability or unwillingness to comply with protocol.~11. Well controlled on current ADHD treatment.~12. Inability to take oral capsules.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Open Label Phase Then 2-week Double Blind Phase (Placebo First, Then Methylphenidate HCl ER Capsule) (Type: EXPERIMENTAL): Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Placebo: Capsule without active drug for 1 week Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Dosed once daily in the morning
- Open Label Phase Then 2-week Double Blind Phase (Methylphenidate HCl ER Capsule First, Then Placebo) (Type: EXPERIMENTAL): Open Label Phase: Subjects were dose optimized over a 2 to 4 week period. All subjects began at an initial Methylphenidate hydrochloride extended release capsules dose of 15 mg and were titrated weekly to an optimal dose using strengths of 15, 20, 30, up to the maximum of 40 mg/day.~Double Blind Phase (2-weeks):~Methylphenidate HCl ER Capsule: An optimized dose of Methylphenidate hydrochloride extended release capsules (15, 20, 30, or 40 mg) for 1 week Placebo: Capsule without active drug for 1 week Dosed once daily in the morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete